Pharco Pharmaceuticals Launches “Vision for All” Initiative to Strengthen Ophthalmic Healthcare in Egypt with EGP 500 Million Investment
Cairo, Egypt — Pharco Pharmaceuticals has officially launched its “Vision for All” initiative, aimed at enhancing ophthalmic healthcare services throughout Egypt and the surrounding region. This initiative focuses on early detection programs for eye diseases, particularly glaucoma, and includes participation in medical convoys under the broader “Nour Einak” (Light of Your Eyes) initiative. The program also involves donating specialized medical equipment to healthcare institutions in underserved governorates, organizing physician training programs, and developing digital patient follow-up tools in collaboration with relevant scientific organizations.
Digital Transformation in Healthcare Delivery
Pharco’s initiative aligns with a strategic shift toward digital transformation in healthcare. The company is developing an integrated electronic patient management system that includes treatment reminder tools and an electronic medical record platform. This system is designed to facilitate precise case monitoring in coordination with medical authorities, fostering collaboration between the pharmaceutical industry and the healthcare community. Such advancements are expected to create a more sustainable model for healthcare service delivery.
Collaboration with Medical Societies
At the launch event, Pharco signed a cooperation protocol with the Egyptian Ophthalmological Society and the Egyptian Society for the Glaucomas. This agreement aims to support glaucoma patients by providing intraocular pressure measurement services, raising public awareness about the disease, and enhancing access to medical services for vulnerable populations. The protocol was signed by Dr. Sherine Helmy, Chairman of Pharco Pharmaceuticals; Professor Khaled Morad, President of the Egyptian Ophthalmological Society; and Professor Mostafa Nassar, President of the Egyptian Society for the Glaucomas. The signing was attended by Dr. Amr Saleh, General Manager of the Oncology and Ophthalmology Division, along with members of both societies and leading ophthalmology experts from Egypt and the region.
New Production Line for Ophthalmic Eye Drops
The launch of the “Vision for All” initiative coincides with the commissioning of a new ophthalmic eye drops production line at Pharco’s facility in Amreya City, Alexandria. This production line has been constructed in compliance with the latest Good Manufacturing Practice (GMP) standards, meeting the requirements set by the Egyptian Drug Authority (EDA) and international regulatory frameworks. The total investment for this project exceeds EGP 500 million, with approximately EGP 300 million allocated specifically for the production line. This investment reflects Pharco’s strategic focus on ophthalmology, a therapeutic area experiencing growing demand in Egypt and across the Middle East and Africa.
Commitment to Pharmaceutical Security
Dr. Sherine Helmy emphasized that the launch of the “Vision for All” initiative, alongside the new production line, signifies Pharco’s commitment to modern pharmaceutical manufacturing, which extends beyond merely providing high-quality medicines. She stated that it encompasses prevention, early detection, and the establishment of effective partnerships with healthcare institutions. Dr. Helmy described the project as a strategic milestone for localizing advanced pharmaceutical manufacturing in Egypt, reinforcing Pharco’s role as a national partner in pharmaceutical security, which is vital for Egypt’s national security.
Pharco’s investment of over EGP 500 million in this project underscores its dedication to industrial expansion and the belief that the future of pharmaceutical manufacturing relies on world-class quality and advanced technology.
Expanding Access to Ophthalmic Services
Pharco has actively participated in the “Nour Einak” initiative, conducting medical convoys and scientific activities in collaboration with universities, healthcare institutions, and medical societies. These efforts aim to increase early detection rates and expand service coverage in underserved areas. The initiative also includes providing specialized medical equipment, such as a dedicated dry eye treatment unit to Minya University, in partnership with the Egyptian Ophthalmological Society, the Egyptian Glaucoma Society, the Universal Health Insurance Authority, and the Unified Procurement Authority.
The growing demand for ophthalmic healthcare in Egypt is underscored by an estimated market of over 100 million packs and 16.7 million prescriptions annually. Approximately one million Egyptian patients are living with glaucoma, and there is a widespread prevalence of dry eye syndrome. These factors highlight the necessity of establishing advanced production capacities to enhance drug availability and responsiveness to patient needs. The new production line is expected to deliver an annual production capacity of up to 20 million packs, covering about 19% of Egypt’s domestic demand for ophthalmic preparations and addressing approximately 11% of the combined demand from Egypt, the Middle East, and Africa, which is estimated at around 177 million packs annually.
Source: www.zawya.com
Read all the latest developments and breaking updates in the Latest News section.
Published on 2026-05-03 18:01:00 • By the Editorial Desk
